Vireo Growth Expands Stake in Schwazze Convertible Notes
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vireo Growth ( (TSE:VREO) ) has issued an update.
On December 19, 2025, Vireo Growth Inc. announced that it entered into agreements to acquire additional senior secured convertible notes of Medicine Man Technologies Inc. (dba Schwazze) from third-party holders, increasing its stake to about 89% of Schwazze’s outstanding 13% senior secured convertible notes due December 7, 2026. Vireo is purchasing notes with approximately $2.6 million in principal plus accrued interest for roughly $1.6 million, paying with subordinate voting shares priced at $0.54, in a transaction expected to close by December 31, 2025, subject to Canadian Securities Exchange approval; the notes, on which Schwazze is currently in payment default, are secured by a mix of junior and first-priority interests in Schwazze’s operating assets and subsidiaries, potentially strengthening Vireo’s creditor position and strategic influence over a distressed peer while introducing equity dilution and highlighting governance sensitivities given its CEO’s affiliation with the collateral agent group.
More about Vireo Growth
Vireo Growth Inc., founded in 2014, is a U.S.-based cannabis company that began as a pioneering medical cannabis operator and is building a disciplined, execution-focused platform across the industry. The company emphasizes a local market focus supported by a national portfolio, deploying capital and talent where it expects the greatest returns, and positions itself as a long-term oriented operator committed to customers, employees, shareholders, partners, and the communities it serves.
YTD Price Performance: 4.94%
Average Trading Volume: 78,506
Technical Sentiment Signal: Buy
Current Market Cap: C$905M
For a thorough assessment of VREO stock, go to TipRanks’ Stock Analysis page.
